There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...
Renal cell carcinoma (RCC) exhibits significant heterogeneity, making it challenging to predict tumor aggressiveness and therapeutic response. To improve prognostic accuracy and develop tailored ...
Health and Me on MSN
Young adults and kidney cancer: A changing trend?
Although kidney cancer remains relatively uncommon in young adults, it is not unheard of. Large surgical series have found ...
Metabolic reprogramming is a hallmark characteristic of renal cell carcinoma (RCC). SIRT3, a key mitochondrial deacetylase, plays a crucial role in metabolic reprogramming. However, its contribution ...
In RCC, a phase I study of a neoantigen-targeting personalized cancer vaccine in the adjuvant setting was successful in eliciting antigen-specific and tumor-directed immune responses. 77 These studies ...
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor ...
For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...
Most people know that obesity increases risk for developing diabetes, heart disease, and high blood pressure; however, what ...
This is a prospective study of all patients with metastatic RCC unselected for high-risk features, registered at our center between September 2023 and August 2024. Baseline clinicopathologic details ...
A personalized cancer vaccine targeting neoantigens in high-risk renal cell carcinoma (RCC) demonstrates promising results, with no disease recurrence in any of the nine participants over a 40.2-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results